BACKGROUND: The conjugate Haemophilus influenzae type b (Hib) vaccine has been highly efficacious in reducing type b H. influenzae meningitis. However, information is limited about its impact on childhood pneumonia after vaccine introduction into the routine programme. This study evaluated the effectiveness of Hib conjugate vaccine in the reduction of community-acquired pneumonia among infants in Central Brazil. METHODS: A matched case-control study was built into an ongoing prospective population-based surveillance of pneumonia, enrolling 1293 participants between May 2000 and August 2001. Cases (n = 431) were children <or=2 years old hospitalized with radiologically definite pneumonia according to the World Health Organization standard criteria for the interpretation of radiographs for the diagnosis of pneumonia. Two controls (n = 862) without previous hospitalization for pneumonia were identified among children from the same neighbourhood and matched to cases by age stratum (+/-4 months). The Hib vaccination effectiveness was estimated as 1 minus odds ratio (OR). RESULTS: The greatest risk factor for pneumonia among children <2 years of age was day-care centre attendance (P < 0.001). Of the study participants, 83.3% (1072/1287) were classified as vaccinated according to immunization card and 16.7% (215/1287) were considered unvaccinated. By using conditional logistic regression the vaccine effectiveness was estimated as 31.0% (95% CI: -9.0%, 57.0%) after adjusting for sex, previous flu-like illnesses, day-care attendance, smokers at home, house ownership, mother's education, and age as continuous variable. CONCLUSION: Under programme conditions the effectiveness of Hib conjugate vaccine in infants with radiologically confirmed pneumonia was 31% (95% CI: -9%, 57%) showing the potential benefit of Hib immunization in the prevention of likely non-bacteraemic pneumonia.
BACKGROUND: The conjugate Haemophilus influenzae type b (Hib) vaccine has been highly efficacious in reducing type b H. influenzaemeningitis. However, information is limited about its impact on childhood pneumonia after vaccine introduction into the routine programme. This study evaluated the effectiveness of Hib conjugate vaccine in the reduction of community-acquired pneumonia among infants in Central Brazil. METHODS: A matched case-control study was built into an ongoing prospective population-based surveillance of pneumonia, enrolling 1293 participants between May 2000 and August 2001. Cases (n = 431) were children <or=2 years old hospitalized with radiologically definite pneumonia according to the World Health Organization standard criteria for the interpretation of radiographs for the diagnosis of pneumonia. Two controls (n = 862) without previous hospitalization for pneumonia were identified among children from the same neighbourhood and matched to cases by age stratum (+/-4 months). The Hib vaccination effectiveness was estimated as 1 minus odds ratio (OR). RESULTS: The greatest risk factor for pneumonia among children <2 years of age was day-care centre attendance (P < 0.001). Of the study participants, 83.3% (1072/1287) were classified as vaccinated according to immunization card and 16.7% (215/1287) were considered unvaccinated. By using conditional logistic regression the vaccine effectiveness was estimated as 31.0% (95% CI: -9.0%, 57.0%) after adjusting for sex, previous flu-like illnesses, day-care attendance, smokers at home, house ownership, mother's education, and age as continuous variable. CONCLUSION: Under programme conditions the effectiveness of Hib conjugate vaccine in infants with radiologically confirmed pneumonia was 31% (95% CI: -9%, 57%) showing the potential benefit of Hib immunization in the prevention of likely non-bacteraemic pneumonia.
Authors: Evropi Theodoratou; Sue Johnson; Arnoupe Jhass; Shabir A Madhi; Andrew Clark; Cynthia Boschi-Pinto; Sunil Bhopal; Igor Rudan; Harry Campbell Journal: Int J Epidemiol Date: 2010-04 Impact factor: 7.196
Authors: Núria Díez-Padrisa; Quique Bassat; Sonia Machevo; Llorenç Quintó; Luis Morais; Tacilta Nhampossa; Cristina O'Callaghan-Gordo; Antoni Torres; Pedro L Alonso; Anna Roca Journal: PLoS One Date: 2010-10-14 Impact factor: 3.240
Authors: Shabir A Madhi; Orin S Levine; Rana Hajjeh; Osman D Mansoor; Thomas Cherian Journal: Bull World Health Organ Date: 2008-05 Impact factor: 9.408
Authors: Lícia K A M Thörn; Ruth Minamisava; Simonne S Nouer; Luiza H Ribeiro; Ana Lucia Andrade Journal: BMC Infect Dis Date: 2011-06-22 Impact factor: 3.090
Authors: Jennifer R Verani; Abdullah H Baqui; Claire V Broome; Thomas Cherian; Cheryl Cohen; Jennifer L Farrar; Daniel R Feikin; Michelle J Groome; Rana A Hajjeh; Hope L Johnson; Shabir A Madhi; Kim Mulholland; Katherine L O'Brien; Umesh D Parashar; Manish M Patel; Laura C Rodrigues; Mathuram Santosham; J Anthony Scott; Peter G Smith; Halvor Sommerfelt; Jacqueline E Tate; J Chris Victor; Cynthia G Whitney; Anita K Zaidi; Elizabeth R Zell Journal: Vaccine Date: 2017-04-22 Impact factor: 3.641
Authors: M Carolina Danovaro-Holliday; Salvador Garcia; Ciro de Quadros; Gina Tambini; Jon K Andrus Journal: PLoS Med Date: 2008-04-22 Impact factor: 11.069
Authors: Stephen B Gordon; Nigel G Bruce; Jonathan Grigg; Patricia L Hibberd; Om P Kurmi; Kin-bong Hubert Lam; Kevin Mortimer; Kwaku Poku Asante; Kalpana Balakrishnan; John Balmes; Naor Bar-Zeev; Michael N Bates; Patrick N Breysse; Sonia Buist; Zhengming Chen; Deborah Havens; Darby Jack; Surinder Jindal; Haidong Kan; Sumi Mehta; Peter Moschovis; Luke Naeher; Archana Patel; Rogelio Perez-Padilla; Daniel Pope; Jamie Rylance; Sean Semple; William J Martin Journal: Lancet Respir Med Date: 2014-09-02 Impact factor: 30.700